A 17-gene stemness score for rapid determination of risk in acute leukaemia

Nature

Volumn 540, Issue 7633, 2016, Pages 433-437

  Ng, Stanley W K ^a   Mitchell, Amanda ^b   Kennedy, James A ^b,c,d   Chen, Weihsu C ^b   McLeod, Jessica ^b   Ibrahimova, Narmin ^b   Arruda, Andrea ^b   Popescu, Andreea ^b   Gupta, Vikas ^b,c,d   Schimmer, Aaron D ^b,c,d   Schuh, Andre C ^b,c,d   Yee, Karen W ^b,c,d   Bullinger, Lars ^e   Herold, Tobias ^f,g   Görlich, Dennis ^h   Büchner, Thomas ^h   Hiddemann, Wolfgang ^f,g   Berdel, Wolfgang E ^h   Wörmann, Bernhard ⁱ   Cheok, Meyling ^j   Preudhomme, Claude ^k   Dombret, Hervé ^l   Metzeler, Klaus ^f,g   Buske, Christian ^e   Löwenberg, Bob ^m   Valk, Peter J M ^m   Zandstra, Peter W ^a   Minden, Mark D ^b,c,d   Dick, John E ^b,d   Wang, Jean C Y ^b,c,d   more..

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f UNIVERSITY OF MUNICH   (Germany)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

ⁱ CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^j JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^k LILLE UNIVERSITY HOSPITAL   (France)

^l SAINT LOUIS HOSPITAL   (France)

^m ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER; TRANSCRIPTOME;

BIOMARKER; CANCER; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; GENE EXPRESSION; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL;

ACUTE LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER RISK; CANCER SURVIVAL; CELL FRACTIONATION; CLINICAL OUTCOME; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC ALGORITHM; GENETIC RISK; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; LEUKEMIA REMISSION; MOUSE; NONHUMAN; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; TUMOR ENGRAFTMENT; XENOTRANSPLANTATION; ALGORITHM; ALLOTRANSPLANTATION; ANIMAL; CANCER STEM CELL; COHORT ANALYSIS; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; PROGNOSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VALIDATION STUDY;

ALGORITHMS; ANIMALS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; NEOPLASTIC STEM CELLS; PROGNOSIS; RISK ASSESSMENT; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSCRIPTOME; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85016147467     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature20598     Document Type: Article

References (53)

1. Ferrara, F. & Schiffer, C. A. Acute myeloid leukaemia in adults. Lancet 381, 484-495 (2013)
2. Grimwade, D. et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116, 354-365 (2010)
3. Döhner, H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115, 453-474 (2010)
4. Röllig, C. et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet recommendations: evaluation of the proposed reporting system. J. Clin. Oncol. 29, 2758-2765 (2011)
5. Walter, R. B. et al. Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center. Leukemia 29, 312-320 (2015)
6. Kreso, A. & Dick, J. E. Evolution of the cancer stem cell model. Cell Stem Cell 14, 275-291 (2014)
7. Saito, Y. et al. Identification of therapeutic targets for quiescent, chemotherapyresistant human leukemia stem cells. Sci. Transl. Med. 2, 17ra9 (2010)
8. Li, L. et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell 15, 431-446 (2014)
9. Fong, C. Y. et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature 525, 538-542 (2015)
10. Lechman, E. R. et al. miR-126 regulates distinct self-renewal outcomes in normal and malignant hematopoietic stem cells. Cancer Cell 29, 214-228 (2016)
11. Eppert, K. et al. Stem cell gene expression programs influence clinical outcome in human leukemia. Nature Med. 17, 1086-1093 (2011)
12. Sarry, J. E. et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2R c-deficient mice. J. Clin. Invest. 121, 384-395 (2011)
13. Laurenti, E. et al. The transcriptional architecture of early human hematopoiesis identifies multilevel control of lymphoid commitment. Nature Immunol. 14, 756-763 (2013)
14. Novershtern, N. et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell 144, 296-309 (2011)
15. Verhaak, R. G. et al. Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling. Haematologica 94, 131-134 (2009)
16. Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. J. Stat. Softw. 33, 1-22 (2010)
17. Simon, N., Friedman, J., Hastie, T. & Tibshirani, R. Regularization paths for Cox's proportional hazards model via coordinate descent. J. Stat. Softw. 39, 1-13 (2011)
18. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059-2074 (2013)
19. Metzeler, K. H. et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 112, 4193-4201 (2008)
20. Grimwade, D., Ivey, A. & Huntly, B. J. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood 127, 29-41 (2016)
21. Papaemmanuil, E. et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl. J. Med. 374, 2209-2221 (2016)
22. Levine, J. H. et al. Data-driven phenotypic dissection of AML reveals progenitorlike cells that correlate with prognosis. Cell 162, 184-197 (2015)
23. Gentles, A. J., Plevritis, S. K., Majeti, R. & Alizadeh, A. A. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. J. Am. Med. Assoc. 304, 2706-2715 (2010)
24. Jung, N., Dai, B., Gentles, A. J., Majeti, R. & Feinberg, A. P. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nature Commun. 6, 8489 (2015)
25. Geiss, G. K. et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature Biotechnol. 26, 317-325 (2008)
26. Cornelissen, J. J. et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach. Nature Rev. Clin. Oncol. 9, 579-590 (2012)
27. Kohlmann, A. et al. Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 24, 1216-1220 (2010)
28. Castaigne, S. et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 379, 1508-1516 (2012)
29. Hills, R. K. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15, 986-996 (2014)
30. Klco, J. M. et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. J. Am. Med. Assoc. 314, 811-822 (2015)
31. Du, P., Kibbe, W. A. & Lin, S. M. lumi: a pipeline for processing Illumina microarray. Bioinformatics 24, 1547-1548 (2008)
32. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015)
33. Qiao, W. et al. PERT: a method for expression deconvolution of human blood samples from varied microenvironmental and developmental conditions. PLOS Comput. Biol. 8, e1002838 (2012)
34. Gautier, L., Cope, L., Bolstad, B. M. & Irizarry, R. A. affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 20, 307-315 (2004)
35. Wu, J., Irizarry, R., MacDonald, J. & Gentry, J. Gcrma: background adjustment using sequence information. R package version 2.36.0 (2016)
36. Dai, M. et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 33, e175 (2005)
37. Macrae, T. et al. RNA-seq reveals spliceosome and proteasome genes as most consistent transcripts in human cancer cells. PLoS ONE 8, e72884 (2013)
38. Scott, D. W. et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123, 1214-1217 (2014)
39. Nielsen, T. et al. Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer 14, 177 (2014)
40. R Development Core Team. A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, 2014)
41. Cheson, B. D. et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J. Clin. Oncol. 21, 4642-4649 (2003)
42. Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat. 16, 1141-1154 (1988)
43. Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496-509 (1999)
44. Gray, B. cmprsk: subdistribution analysis of competing risks. R package version 2.2-7 (2014)
45. Gerds, T. A. & Scheike, T. H. riskRegression: risk regression for survival analysis. R package version 0.0.8 (2016)
46. Kanda, Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 48, 452-458 (2013)
47. Mantel, N. & Byar, D. Evaluation of response-time data involving transient states: an illustration using heart transplant data. J. Am. Stat. Assoc. 69, 81-86 (1974)
48. Andersen, P. & Gill, R. D. Cox's regression model for counting processes: a large sample study. Ann. Stat. 10, 1100-1120 (1982)
49. Simon, R. & Makuch, R. W. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Stat. Med. 3, 35-44 (1984)
50. Therneau, T. M. & Grambsch, P. M. Modeling Survival Data: Extending the Cox Model (Springer, 2000)
51. Harrell, F. E. Jr. rms: regression modeling strategies. R package version 4.4-1 (2016)
52. Robin, X. et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 12, 77 (2011)
53. Kundu, S., Aulchenko, Y. S., van Duijn, C. M. & Janssens, A. C. PredictABEL: an R psackage for the assessment of risk prediction models. Eur. J. Epidemiol. 26, 261-264 (2011).